Office of Cellular Tissue and Gene Therapies Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Cellular, Tissue, and.

Slides:

Advertisements

Similar presentations

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Advertisements

Center for Biologics Evaluation and Research

The Division of Monoclonal Antibodies Kathleen A. Clouse, Ph.D., Director CTGTAC - July 26, 2007.

Mitochondrial Manipulation Technologies: Preclinical Considerations

FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division.

FDA IND Review: Regulations and Challenges

FDA Regulation of Cell Therapy

Office of Biotechnology Products

An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

1 About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events.

1 Overview: Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies Raj K. Puri, M.D., Ph.D. Director, DCGT Office of Cellular,

1 DCGT research priorities: Led by Critical Path Challenges Virology Retroviruses, lentivirus, adeno, filovirus Immunology Anti-viral immunity, immunobiology.

1 FDA Regulation of Cellular, Tissue, and Gene Therapies Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies, FDA Phacilitate.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development RAID Training.

Cellular Tissue and Gene Therapies Research Site Visit Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies September 29,

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

Component 1: Introduction to Health Care and Public Health in the US Unit 6- Regulating Health Care Lecture a- Regulatory Agencies— JCAHO, FDA, AMA, &

Bernard A Fox, PhD Immediate Past President and Chair, Executive Council Society for Immunotherapy of Cancer (SITC) Defining the Critical Hurdles in Cancer.

Associate Director for Research, OCTGT

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

OCTGT Overview Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies CTGTAC Meeting July 26, 2007.

Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.

Innovation Through Collaboration: Why the CSS Working Groups are Important to the FDA Steve Wilson, DrPH, CAPT USPHS Director, FDA/CDER/OTS/OB/DBIII 2014.

Division of Hematology Basil Golding M.D. Division Director Site Visits 2010 Laboratories of Hemostasis, and Plasma Derivatives.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

Raj K. Puri, M.D., Ph.D. Director, DCGT

Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

1 Overview of the Laboratory of Hepatitis Viruses March 20, 2014 VRBPAC Discussion of the December 5, 2013 Site Visit for the Laboratory of Hepatitis Viruses.

Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

1 In memory, Dr. Eda T. Bloom Immunology researcher – Mentor Regulator – Public health policy contributor Treasured colleague and friend We mourn this.

The International Society For Cellular Therapy. Mission Statement ISCT is a global association driving the translation of scientific research to deliver.

Biologics and Genetic Therapies Directorate Health Products and Food Branch HEALTH CANADA Helping Canadians maintain and improve their health. Agnes Klein.

Center for Biologics Evaluation and Research, FDA Kathryn M. Carbone, M.D. Associate Director for Research.

FDA EID Workshop: Day 2 Organs, Tissues and Cells Melissa A. Greenwald, MD Blood Products Advisory Committee 26 July 2010 Gaithersburg, MD.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

FDA’s Critical Path Research Initiative & Intro to the CBER Research Program Kathryn M. Carbone, M.D. Associate Director for Research CBER/FDA.

Division of Cellular and Gene Therapies (DCGT) Overview of Activities Raj K. Puri, M.D., Ph.D. Division Director, Division of Cellular and Gene Therapies.

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Office of Vaccines Research and Review

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

The Regulatory Science of Regenerative Medicine Celia M. Witten, Ph.D., M.D., Director Office of Cellular, Tissue and Gene Therapies Center for Biologics.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue, and Gene Therapies Web Seminar Series presents:

Office of Science Statement on Digital Data Management Laura Biven, PhD Senior Science and Technology Advisor Office of the Deputy Director for Science.

Critical Path Initiative Sousan S. Altaie, Ph.D. Scientific Policy Advisor OIVD/CDRH.

Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February 26, 2014.

Functional Vision Endpoints: OCTGT Perspective Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Center for Biologics Evaluation and.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

CBER FDA Science Board Office of Cellular, Tissue, and Gene Therapies (OCTGT) Kathryn C. Zoon, PhD October 25, 2002.

Division of Cellular and Gene Therapies (DCGT)

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

CBER Research: OCTGT Office Site Visit Carolyn A. Wilson, Ph.D. Associate Director of Research (Acting) CBER/FDA.

NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.

Georgetown UNIVERSITY Overview of Gene Transfer as an Evolving Neurotherapeutic Modality Howard J Federoff, MD, PhD Georgetown University Medical Center.

CLI and Device Intervention Across the Pacific – An FDA View

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Lessons Learned: Past Present and Future Japan-USA Regulatory Interactions Erica Takai, PhD US Food and Drug Administration

Innovation: A Priority for FDA

Patient Involvement in the Development and Safe Use of

Trial Funding and Engagement: The NIH Sponsored CTSA Program

Presentation transcript:

Office of Cellular Tissue and Gene Therapies Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Cellular, Tissue, and Gene Therapies Advisory Committee Meeting February 10, 2006

OCTGT Mission Facilitate development, approval, and access to safe and effective medical products

Outline Science in Research and Review Products Regulated Office Overview

Science in Research and Review: Critical Path Initiative Bring scientific advances to medical product development process (simulation models, validated biomarkers, new clinical trial designs) Stimulate development of applicable research programs in critical path scientific areas, aim to develop techniques that address challenges encountered during product development Regulatory guidance/practice and standards to reflect best available science, integrate FDA involvement

Patients Research Community FDA PublicSponsors Practitioners/Societies Payors

OCTGT Regulation Cellular therapies Tumor vaccines Gene therapies Tissue and tissue based products Xenotransplantation products Combination products Devices used for cells/tissues Anti-idiotype antibodies

Office of Cellular, Tissue, and Gene Therapies Celia M.Witten, Ph.D, M.D. Office Director Eda Bloom, Ph.D. Acting Deputy Director Suzanne Epstein, Ph.D., Associate Director for Research Richard McFarland, M.D., Ph.D. Acting Associate Director for Policy Division of Cellular and Gene Therapies Raj Puri, Ph.D., M.D., Director Stephanie Simek, Ph.D., Deputy Director Division of Human Tissue Products Ruth Solomon, M.D., Director Division of Clinical Evaluation and Pharmacology/Toxicology Ashok Batra, M.D.

DCGT Reorganization Consolidate research-reviewer PIs with similar background Branch names reflect regulatory responsibilities Critical mass and efficient operations

Division of Cellular and Gene Therapies Raj Puri, Ph.D., M.D., Division Director Stephanie Simek, Ph.D., Deputy Director Cellular and Tissue Therapy Branch Steve Bauer, Ph.D., Acting Chief Tumor Vaccines and Biotechnology Branch Raj Puri, Ph.D., M.D., Acting Chief Cell Therapies Branch Kimberly Benton, Ph.D., Chief Gene Therapies Branch Maritza McIntyre, Ph.D., Chief Gene Transfer and Immunogenicity Branch Eda Bloom, Ph.D., Chief New Structure